Skip to main content

CORRECTION article

Front. Oncol., 26 October 2022
Sec. Molecular and Cellular Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1038279
This article is part of the Research Topic Metabolic Regulation under Oxidative Stress in Cancer View all 13 articles

Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism

This article is a correction to:

  1. OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism

    1. Read original article
Jie Wen*&#x;Jie Wen1*†Abudureyimujiang Aili&#x;Abudureyimujiang Aili2†Yao Xue Yan&#x;Yao Xue Yan3†YuLin LaiYuLin Lai4Shaoqing NiuShaoqing Niu4Shasha HeShasha He4Xiaokai ZhangXiaokai Zhang5Guixiong ZhangGuixiong Zhang5Jiaping Li*Jiaping Li5*
  • 1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China and Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China
  • 2Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China
  • 3Department of Dermatology, Peking University People’s Hospital, Beijing, China
  • 4Deparment of Radiotherapy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • 5Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

A Corrigendum on:
OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism

by Wen J, Aili A, Yan YX, Lai Y, Niu S, He S, Zhang X, Zhang G, Li J. (2022) Front. Oncol. 12:977348. doi: 10.3389/fonc.2022.977348

In the published article, there was an error in the author list, and authors Abudureyimujinag Aili, Yao Xue Yan were erroneously excluded from co-first authorship. Jie Wen, Abudureyimujiang Aili, Yao Xue Yan should be co-first authors. The corrected author list appears below.

Jie Wen1*†, Abudureyimujiang Aili2†, Yao Xue Yan3†, YuLin Lai4, Shaoqing Niu4, Shasha He4, Xiaokai Zhang5, Guixiong Zhang5 and Jiaping Li5*

†These authors have contributed equally to this work and share first authorship.

In the published article, there was an error in the Funding statement. There was a grammatical error and two funders were missed. The correct Funding statement appears below.

This work was Funded by China Postdoctoral Science Foundation to Jie Wen (2020M683115), the National Natural Science Foundation of China (No. 81971719 to Jiaping Li, 81903037 to Shasha He, 81902909 to Abudureyimujiang Aili and 82102818 to Wenjie), the Guangdong Medical Research Foundation (No. A2022121 to Shaoqing Niu), the Major Science and Technology Program of Guangdong Province (No. 2020B0101130016 to Jiaping Li) and the Guangzhou Key research and development Projects (No. 202103000021 to Jiaping Li).

In the published article, there was an error in the description of Malondialdehyde (MDA) measurement. A correction has been made to Methods, Malondialdehyde (MDA) measurement, line 239-245 in Paragraph 4 of Page 6. This sentence previously stated:

“The calculation method was as follows:

Δod was as follows calculation m

Δod was as follows calculation m

Δod waA600 (sample)-A600 (blank)

MDA (nmol/mgprot) =5 × 12.9ot) =55) =5t) =5A600 (blankSpr (sample protein concentration, 232 mg/mL).”

The corrected sentence appears below:

“ΔA450=A450 (sample)-A450 (blank)

ΔA532=A532 (sample)-A532 (blank)

ΔA600=A600 (sample)-A600 (blank)

MDA (nmol/mgprot) =5×(12.9×(ΔA532-ΔA600)-2.58×ΔA450)÷Spr (sample protein concentration, mg/mL).”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: HCC, OIT3, ferroptosis, arachidonic acid, biomarker

Citation: Wen J, Aili A, Yan YX, Lai Y, Niu S, He S, Zhang X, Zhang G and Li J (2022) Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism. Front. Oncol. 12:1038279. doi: 10.3389/fonc.2022.1038279

Received: 06 September 2022; Accepted: 14 October 2022;
Published: 26 October 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Wen, Aili, Yan, Lai, Niu, He, Zhang, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jie Wen, wenj67@mail.sysu.edu.cn; Jiaping Li, lijiap@mail.sysu.edu.cn

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.